1. World Health Organization. Global Tuberculosis Control. WHO Report 2022. [
Article]
2. Moatamedizadeh B, Ansari H, Payandeh A, et al. Evaluation of Tuberculosis Recurrence and Its Determinants in the Southeast of Iran: A Nested Case-Control Study Based on Data from 2012 to 2018. Irje 2020; 16(1): 20-29. (Persian) [
Article]
3. Torshizi F, Honarvar M, Rahimarbabi E, et al. Incidence and treatment outcomes of pulmonary tuberculosis in Islamic Republic of Iran. East Mediterr Health J 2023; 29(6): 417-424. [
DOI]
4. Najafi Vosogh R, Roshanaei G, Khazaei S, et al. Study of Tuberculosis epidemiology and its affected factors in Hamadan province, during the years 2007-2013. Pajouhan Sci J 2015; 14(1): 64-71. (Persian) [
Article]
5. World Health Organization. The sixteenth global report on tuberculosis 2011. [
Article]
6. Khazaei S, Kousehlou Z, Karami M, et al. Time to sputum conversion among patients with smearpositive pulmonary tuberculosis and its determinants: A retrospective cohort study in Hamadan Province, Iran. Irje 2013; 9(1): 32-40. (Persian) [
Article]
7. Kim L, Moonan PK, Heilig CM, et al. Factors associated with recurrent tuberculosis more than 12 months after treatment completion. Int J Tuberc Lung Dis 2016; 20(1): 49-56. [
DOI]
8. Harding JS, Herbath M, Chen Y, et al. VEGF-A Form Granuloma Macrophages Regulates Granulomatous Inflammation by a Non-angiogenic Pathway during Mycobacterial Infection. Cell Rep 2019; 27(7): 2119-2131.e6. [
DOI]
9. Laddha AP, Kulkarni YA. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders. Respir Med 2019; 156: 33-46. [
DOI]
10. Maison DP. Tuberculosis pathophysiology and anti-VEGF intervention. J Clin Tuberc Other Mycobact Dis 2022; 27: 100300. [
DOI]
11. Kumar V, Abbas A, Aster J. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier, 2020, 268-274.
12. Bourhis M, Palle J, Galy-Fauroux I, et al. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment. Front Immunol 2021; 12: 616837. [
DOI]
13. Korolkova OY, Myers JN, Pellom ST, et al. Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides. Clin Med Insights Gastroenterol 2015; 8: 29-44. [
DOI]
14. Saghazadeh A, Rezaei N. Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis. PLoS One 2022; 17(5): e0268543. [
DOI]
15. Li Z, Li C, Bao R, et al. Expressions of miR29a, TNF-Α and Vascular Endothelial Growth Factor in Peripheral Blood of Pulmonary Tuberculosis Patients and Their Clinical Significance. Iran J Public Health 2020; 49(9): 1683-1691. [
DOI]
16. Nasiri N, Avan A, Hassanian SM, et al. Effect of anti-angiogenic drugs along with chemotherapy in breast cancer treatment: review article. Iran J Obstet Gynecol Infertil 2019; 22(5): 78-89. (Persian) [
DOI]
17. Oehlers SH, Cronan MR, Scott NR, et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature 2015; 517(7536): 612-615. [
DOI]
18. de Martino M, Lodi L, Galli L, et al. Immune Response to Mycobacterium tuberculosis: A Narrative Review. Front Pediatr 2019; 7: 350. [
DOI]
19. Metanat M, Sharifi-Mood B, Alavi-Naini R, et al. The epidemiology of tuberculosis in recent years: Reviewing the status in south-eastern Iran. Zahedan J Res Med Sci 2011; 13(9): e93704. [
Article]
20. Moslehi A, Moslehi A. Evolution of extant antibody effect on natural platelets and neutrophils in people with platelet satellitism. Qom Univ Med Sci J 2016; 10(7): 84-88. (Persian) [
DOI]
21. Batista LAF, Silva KJS, da Costa e Silva LM, et al. Tuberculosis: A granulomatous disease mediated by epigenetic factors. Tuberculosis 2020; 123: 101943. [
DOI]
22. Famelis N, Rivera-Calzada A, Degliesposti G, et al. Architecture of the mycobacterial type VII secretion system. Nature 2019; 576(7786): 321-5. [
DOI]
23. Harding J, Ritter A, Rayasam A, et al. Lymphangiogenesis Is Induced by Mycobacterial Granulomas via Vascular Endothelial Growth Factor Receptor-3 and Supports Systemic T-Cell Responses against Mycobacterial Antigen. Am J Pathol 2015; 185(2): 432-45. [
DOI]
24. Golubinskaya EP, Filonenko TG, Kramar TV, et al. Dysregulation of VEGF-dependent angiogenesis in cavernous lung tuberculosis. Pathophysiology 2019; 26(3-4): 381-387. [
DOI]
25. Chen WL, Lee KL, Lai KS, et al. Toll-like Receptor 2 Mediates VEGF Overexpression and Mesothelial Hyperpermeability in Tuberculous Pleural Effusion. Int J Mol Sci 2023; 24(3): 2846. [
DOI]
26. Datta M, Via LE, Kamoun WS, et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A 2015; 112(6): 1827-32. [
DOI]
27. Polena H, Boudou F, Tilleul S, et al. Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination. Sci Rep 2016; 6: 33162. [
DOI]
28. Schlich R, Willems M, Greulich S, et al. VEGF in the crosstalk between human adipocytes and smooth muscle cells: depot-specific release from visceral and perivascular adipose tissue. Mediators Inflamm 2013; 2013: 982458. [
DOI]
29. Tayeboon MA, Sadrnia M, Mohajerani H. Simultaneous detection of TB and drug resistance to Isoniazid in Mycobacterium tuberculosis clinical isolates using PCR-RFLP method. Iran South Med J 2015; 18(3): 547-555. (Persian) [
Article]
30. Golestani Eimani B, Ansarin K, Sahebi L, et al. Molecular Typing of Mycobacterium Tuberculosis Isolated from Iranian Patients Using Highly Abundant Polymorphic GC-Rich-Repetitive Sequence. Iran South Med J 2020; 23(2): 87-98. [
Article]
31. Samsam Shariat M, Parivar K, Hedayati M, et al. Association of Serum VEGF level with Medullary Thyroid Carcinoma in an Iranian Population. J Anim Biol 2016; 9(1): 29-36. (Persian) [
Article]